Log in
NASDAQ:TLRY

Tilray Stock Forecast, Price & News

$6.48
+0.92 (+16.55 %)
(As of 10/19/2020 12:00 AM ET)
Add
Compare
Today's Range
$5.59
Now: $6.48
$6.50
50-Day Range
$4.70
MA: $5.50
$6.71
52-Week Range
$2.43
Now: $6.48
$25.68
Volume18.62 million shs
Average Volume8.52 million shs
Market Capitalization$824.11 million
P/E RatioN/A
Dividend YieldN/A
Beta2.92
Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Nanaimo, Canada.
Read More
Tilray logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.39 out of 5 stars

Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TLRY
CUSIPN/A
CIKN/A
Phone206-432-9325
Employees1,646

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$166.98 million
Book Value$2.78 per share

Profitability

Net Income$-321,170,000.00
Net Margins-259.60%

Miscellaneous

Market Cap$824.11 million
Next Earnings Date11/10/2020 (Estimated)
OptionableOptionable
$6.48
+0.92 (+16.55 %)
(As of 10/19/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TLRY News and Ratings via Email

Sign-up to receive the latest news and ratings for TLRY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Tilray (NASDAQ:TLRY) Frequently Asked Questions

How has Tilray's stock been impacted by COVID-19?

Tilray's stock was trading at $7.09 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, TLRY shares have decreased by 8.6% and is now trading at $6.48.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Tilray?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tilray in the last year. There are currently 1 sell rating, 12 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Tilray
.

When is Tilray's next earnings date?

Tilray is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Tilray
.

How were Tilray's earnings last quarter?

Tilray Inc (NASDAQ:TLRY) announced its earnings results on Monday, August, 10th. The company reported ($0.65) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.27) by $0.38. The business earned $50.41 million during the quarter, compared to analysts' expectations of $54.99 million. Tilray had a negative net margin of 259.60% and a negative return on equity of 77.77%. The company's quarterly revenue was up 9.8% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.32) earnings per share.
View Tilray's earnings history
.

What price target have analysts set for TLRY?

15 analysts have issued twelve-month target prices for Tilray's shares. Their forecasts range from $4.00 to $31.00. On average, they expect Tilray's share price to reach $12.73 in the next year. This suggests a possible upside of 96.4% from the stock's current price.
View analysts' price targets for Tilray
.

Are investors shorting Tilray?

Tilray saw a increase in short interest in September. As of September 30th, there was short interest totaling 23,830,000 shares, an increase of 39.3% from the September 15th total of 17,110,000 shares. Based on an average daily trading volume, of 6,410,000 shares, the short-interest ratio is presently 3.7 days.
View Tilray's Short Interest
.

Who are some of Tilray's key competitors?

What other stocks do shareholders of Tilray own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tilray investors own include Canopy Growth (CGC), Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Square (SQ).

Who are Tilray's key executives?

Tilray's management team includes the following people:
  • Mr. Edward Wood Pastorius Jr., Chief Revenue Officer (Age 50)
  • Mr. Brendan Kennedy, Pres, CEO & Director (Age 46)
  • Mr. Mark Castaneda, CFO, Sec. & Treasurer (Age 53)
  • Dr. Catherine Jacobson, Director of Clinical Research & Member of Medical Advisory Board

When did Tilray IPO?

(TLRY) raised $135 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 9,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company acted as the underwriter for the IPO and Roth Capital Partners and Northland Securities were co-managers.

What is Tilray's stock symbol?

Tilray trades on the NASDAQ under the ticker symbol "TLRY."

How do I buy shares of Tilray?

Shares of TLRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Tilray's stock price today?

One share of TLRY stock can currently be purchased for approximately $6.48.

How big of a company is Tilray?

Tilray has a market capitalization of $824.11 million and generates $166.98 million in revenue each year. The company earns $-321,170,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis. Tilray employs 1,646 workers across the globe.

What is Tilray's official website?

The official website for Tilray is www.tilray.com.

How can I contact Tilray?

Tilray's mailing address is 1100 MAUGHAN ROAD, NANAIMO A1, V9X 1J2. The company can be reached via phone at 206-432-9325.

This page was last updated on 10/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.